May 21, 2018 / 11:53 AM / in 7 months

BRIEF-MyoKardia Says Phase 3 Explorer-Hcm Study Evaluating Mavacamten To Initiate In Q2 2018

May 21 (Reuters) - MyoKardia Inc:

* MYOKARDIA ANNOUNCES DESIGN OF PHASE 3 EXPLORER-HCM STUDY EVALUATING MAVACAMTEN IN SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

* MYOKARDIA INC - PHASE 3 EXPLORER-HCM STUDY EXPECTED TO INITIATE IN Q2 2018, TOPLINE DATA ANTICIPATED IN SECOND HALF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below